Literature DB >> 11862086

Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis.

Henry D Perry1, Sima J Doshi, Eric D Donnenfeld, Grace S Bai.   

Abstract

PURPOSE: To investigate the efficacy of topical cyclosporine A 0.5% as a substitute for corticosteroids in the management of therapeutic keratoplasties for mycotic keratitis.
METHODS: Prospective, nonrandomized interventional case series. Three patients with culture-proven mycotic keratitis underwent therapeutic keratoplasties. All were treated with topical cyclosporine A 0.5% postoperatively as a primary or an adjunctive therapy for prevention of allograft rejection. The patients were followed up from 15 to 42 months for maintenance of graft clarity and best-corrected visual acuity.
RESULTS: Two of three patients maintained clear grafts while using topical cyclosporine A 0.5% twice daily with best-corrected visual acuity of 20/40 and 20/50. One patient developed an opacified graft secondary to preexisting ocular surface disease.
CONCLUSIONS: Topical cyclosporine A 0.5% may be a useful adjunct in the management of therapeutic keratoplasties for mycotic keratitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11862086     DOI: 10.1097/00003226-200203000-00006

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  13 in total

Review 1.  Aspergillus keratitis in vernal shield ulcer--a case report and review.

Authors:  Vandana Jain; Kanupriya Mhatre; Akshay G Nair; Debraj Shome; Sundaram Natarajan
Journal:  Int Ophthalmol       Date:  2010-02-03       Impact factor: 2.031

Review 2.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 3.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

4.  Genotypic identification of Fusarium species from ocular sources: comparison to morphologic classification and antifungal sensitivity testing (an AOS thesis).

Authors:  Eduardo C Alfonso
Journal:  Trans Am Ophthalmol Soc       Date:  2008

5.  Regression of severe corneal stromal neovascularization with topical cyclosporine 0.05% after penetrating keratoplasty for fungal corneal ulcer.

Authors:  Baris Sonmez; Umit Beden; Dilek Erkan
Journal:  Int Ophthalmol       Date:  2007-12-20       Impact factor: 2.031

Review 6.  [Keratomycosis: diagnosis and therapy].

Authors:  W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

Review 7.  Post-keratoplasty Infectious Keratitis: Epidemiology, Risk Factors, Management, and Outcomes.

Authors:  Anna Song; Rashmi Deshmukh; Haotian Lin; Marcus Ang; Jodhbir S Mehta; James Chodosh; Dalia G Said; Harminder S Dua; Darren S J Ting
Journal:  Front Med (Lausanne)       Date:  2021-07-07

8.  Successful salvage therapy of Fusarium endophthalmitis secondary to keratitis: an interventional case series.

Authors:  Grant M Comer; Maxwell S Stem; Stephen J Saxe
Journal:  Clin Ophthalmol       Date:  2012-05-09

Review 9.  Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.

Authors:  Rohan Bir Singh; Lingjia Liu; Ann Yung; Sonia Anchouche; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2021-05-15       Impact factor: 6.268

10.  Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis.

Authors:  Seydi Okumus; Erol Coskun; Mehmet Gurkan Tatar; Erdal Kaydu; Ramazan Yayuspayi; Aysegul Comez; Ibrahim Erbagci; Bulent Gurler
Journal:  BMC Ophthalmol       Date:  2012-08-18       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.